Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Affect Disord. 2018 Feb 27;234:34–37. doi: 10.1016/j.jad.2018.02.089

Figure 1.

Figure 1.

Remission rates in normal- or under-weight and obese II+ participants of CO-MED trial BMI is body mass index, SSRI is selective serotonin reuptake inhibitor. This figure presents the observed remission rates in the escitalopram plus placebo (SSRI monotherapy), sustained release bupropion plus escitalopram (bupropion-SSRI), and extended-release venlafaxine plus mirtazapine (venlafaxine-mirtazapine) treatment arms of Combining Medications to Enhance Depression Outcomes (CO-MED) trial. The number needed to treat (NNT) between two treatment arms were calculated by subtracting the higher observed remission rate from the lower observed remission rate and dividing 100 by this difference.